Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Arix Bioscience plc
  6. News
  7. Summary
    ARIX   GB00BD045071

ARIX BIOSCIENCE PLC

(ARIX)
  Report
Delayed Quote. Delayed London Stock Exchange - 08/05 11:35:13 am
175 GBX   -1.13%
08/02Transaction in own shares
DJ
08/02Total Voting Rights
DJ
07/30Transaction in own shares
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Transaction in own shares

06/14/2021 | 12:21pm EDT
Arix Bioscience PLC (ARIX) 
Transaction in own shares 
14-Jun-2021 / 17:20 GMT/BST 
Dissemination of a Regulatory Announcement, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
 
Arix Bioscience plc 
 
Transaction in own shares 
 
LONDON, 14 June 2021: Arix Bioscience plc ("Arix" or "the Company") (LSE: ARIX), a global venture capital company 
focused on investing in and building breakthrough biotech companies, today announces that it purchased the following 
number of its ordinary shares of 0.001 pence each on the London Stock Exchange from Jefferies International Limited as 
part of a buyback programme announced on 22 March 2021. 
 
Date of purchase                      14 June 2021 
Aggregate number of shares purchased  36,000 
Highest price paid per share          178.98p 
Lowest price paid per share           178.00p 
Average price paid per share          178.49p 

Arix intends to retain the purchased shares in treasury.

Following settlement of the above purchase, Arix will have 131,645,800 ordinary shares of 0.001 pence each in issue (excluding 3,963,853 ordinary shares of 0.001 pence each held in treasury). This number represents the total voting rights in Arix and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No. 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018), the schedule below contains detailed information of the individual trades made by Jefferies International Limited as part of the buyback programme.

[ENDS]

For more information on Arix, please contact:

Arix Bioscience plc

Charlotte Parry, Head of Investor Relations

+44 (0)20 7290 1072

charlotte@arixbioscience.com

Optimum Strategic Communications

Mary Clark, Supriya Mathur, Shabnam Bashir

+44 (0)20 3922 1906

optimum.arix@optimumcomms.com

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

Transaction Date Transaction Time Volume Price (GBp) Platform              Transaction Reference Number 
14/06/2021       08:34:39         18,000 178.00      London Stock Exchange 00245869185TRLO1 
14/06/2021       16:35:00         18,000 178.98      London Stock Exchange 00246135838TRLO1 ----------------------------------------------------------------------------------------------------------------------- 
ISIN:           GB00BD045071 
Category Code:  POS 
TIDM:           ARIX 
LEI Code:       213800OVT3AHQCXNIX43 
OAM Categories: 2.4. Acquisition or disposal of the issuer's own shares 
Sequence No.:   111200 
EQS News ID:    1207835 
 
End of Announcement  EQS News Service 
=------------------------------------------------------------------------------------
 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1207835&application_name=news 
 

(END) Dow Jones Newswires

June 14, 2021 12:20 ET (16:20 GMT)

All news about ARIX BIOSCIENCE PLC
08/02Transaction in own shares
DJ
08/02Total Voting Rights
DJ
07/30Transaction in own shares
DJ
07/28Transaction in own shares
DJ
07/27UPDATE : IP Group's Artios Pharma Raises $153 Million To Fund Cancer Treatment D..
MT
07/27Artios raises USD153m in Series C financing -2-
DJ
07/27Artios raises USD153m in Series C financing
DJ
07/26Transaction in own shares
DJ
07/23Transaction in own shares
DJ
07/21Notice of Results
DJ
More news
Financials
Sales 2021 0,50 M 0,70 M 0,70 M
Net income 2021 37,7 M 52,5 M 52,5 M
Net cash 2021 175 M 244 M 244 M
P/E ratio 2021 6,06x
Yield 2021 -
Capitalization 220 M 307 M 307 M
EV / Sales 2021 89,9x
EV / Sales 2022 98,5x
Nbr of Employees 12
Free-Float 72,3%
Chart ARIX BIOSCIENCE PLC
Duration : Period :
Arix Bioscience plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARIX BIOSCIENCE PLC
Short TermMid-TermLong Term
TrendsNeutralBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 175,00 GBX
Average target price 221,50 GBX
Spread / Average Target 26,6%
EPS Revisions
Managers and Directors
Robert William Henry Lyne CEO, COO, Secretary, Director & General Counsel
Marcus Karia Group Finance Director
Peregrine D. E. M. Moncreiffe Non-Executive Chairman
Graeme Smith Chief Technology Officer
Giles Francis Bertram Kerr Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
ARIX BIOSCIENCE PLC-19.18%309
INVESTOR AB (PUBL)45.27%77 401
CK HUTCHISON HOLDINGS LIMITED4.25%27 888
AB INDUSTRIVÄRDEN (PUBL)28.74%17 525
HAL TRUST29.70%15 323
LIFCO AB (PUBL)64.77%13 685